UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple Turns 50: From Garage Startup to AI Crossroads 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
NEW YORK, Nov. 23, 2016 -- Safirstein Metcalf LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of purchasers of ProNAi Therapeutics, Inc. ("ProNAi") (NASDAQ:DNAI) common stock between July 15, 2015 and June 6, 2016 (the "Class Period").
If you purchased ProNAi securities during the class period, and would like more information about getting involved in the ProNAi Therapeutics Class Action, please contact Sheila Feerick at 1-800-221-0015, or email [email protected].
If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
ProNAi is a clinical stage oncology company with a focus on pioneering a novel class of therapeutics based on its proprietary DNA interference (DNAi) technology platform. Until recently, the Company had only one product candidate – PNT2258, which was purportedly designed to target cancers that overexpress B-cell lymphoma such as Hodgkin’s lymphomas and non-Hodgkin lymphoma.
The complaint alleges that since July 15, 2015, ProNAi and certain of its officers and directors have misrepresented the efficacy and safety of PNT2258, and the drug’s purported attendant capacity for approval by the FDA.
As the Company’s two Phase 2 trials progressed and patient enrollment was ongoing, both the Company’s Chief Scientific Officer and Chief Medical Officer resigned.
On June 6, 2016, the Company issued a press release announcing interim data for the two Phase 2 trials and revealed that PNT2258 had failed to produce sufficient efficacy results to justify its continued clinical development.
Following this news, the price of ProNAi common stock declined more than 67% from a closing share price of $6.38 per share on June 3, 2016 to close at $2.07 per share on June 6, 2016.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP Peter Safirstein, Esq. 1250 Broadway 27th Floor New York, NY 10001 1-800-221-0015 [email protected]
